Menu
ISPOR 2025 United Arab Emirates Chapter Conference Sessions
Session I: “Transforming Healthcare – Patient-Centered Approaches and Personalized Care”
Integrating Patient Preferences in Health Technologies Decision-Making
Session I: “Transforming Healthcare – Patient-Centered Approaches and Personalized Care” Moderated by: Dr. Marleine Moukarzel, Pharmacy Director, Sheikh Shakhbout Medical City, UAE Dr. Lina Wahba, Head of Clinical Pharmacy Services-Tawam- Adjunct Assistant Professor-CMHS UAE university- SEHA pharmacy residency program-Tawam Site director-UAE By: Prof. Ibrahim Alabbadi Professor of Pharmacoeconomics and Pharmaceutical Marketing - The University of Jordan, Jordan
Economic Evaluations and Personalized Care in Healthcare Systems
Session I: “Transforming Healthcare – Patient-Centered Approaches and Personalized Care” Moderated by: Dr. Marleine Moukarzel, Pharmacy Director, Sheikh Shakhbout Medical City, UAE Dr. Lina Wahba, Head of Clinical Pharmacy Services-Tawam- Adjunct Assistant Professor-CMHS UAE
university- SEHA pharmacy residency program-Tawam Site director-UAE By: Prof. Daoud Al-Badriyeh, Professor of Pharmacoeconomics and Outcomes Research at Qatar University, Qatar
Session II: “Redefining Healthcare: Bridging Health Equity and Value-Based Care”
Opening presentation for the panel: “Innovating HEOR for Health Equity: Advancing Value-Based Care, Disease Burden Assessment, and Productivity Measures”
Session II: “Redefining Healthcare: Bridging Health Equity and Value-Based Care” Moderated by: Dr. Aisha ALDhanhani, ISPOR UAE Chapter Board Director, Senior Pharmaceutical Procurement Manager, Rafed, UAE By: Dr. Tomasz Kluszczynski, Professor at Warsaw University of Technology and Goethe Frankfurt University, Poland
Panel Discussion: Advancing Health Equity through Value-Based Healthcare - Economic Burden of Rare Diseases and Orphan Drugs in MENA
Session II: “Redefining Healthcare: Bridging Health Equity and Value-Based Care”
Advancing Health Equity through Value-Based Healthcare - Economic Burden of Rare Diseases and Orphan Drugs in MENA
Chairperson:
Dr. Tomasz Kluszczynski, Professor at Warsaw University of Technology and Goethe Frankfurt University, Poland
Panelists:
Dr. Aisha ALDhanhani, ISPOR UAE Chapter Board Director, Senior Pharmaceutical Procurement Manager, Rafed, UAE
Dr. Amal Yassine, Member of the ISPOR Morocco Chapter Board and General Secretary of the Moroccan Society for Health Products Economics (SMEPS), Morroco
Dr. Khadeija Al-Marshoudi, ISPOR UAE Chapter Board Director, Head of Planning and Development Section at Emirates Health Service, UAE
Dr. Khuloud Jamal Bin Rafeea, Director of Drug compliance and Quality Assurance – DoH, UAE
Dr. Ibtisam Alharbi, Health Economist, Head Pharmacoeconmic unit and Inpatient & IV Oncology Pharmaceutical Services-MODHS, KSA
Prof. Ibrahim Alabbadi, Professor of Pharmacoeconomics and Pharmaceutical Marketing - The University of Jordan, Jordan
Prof. Nadia Al Mazrouei, ISPOR UAE Chapter President and Conference Chair, UAE
Session III: “Balancing Pricing Regulations and Patient Access”
Innovative Pricing & Reimbursement Strategies: Advancing Affordable & PatientCentered Care
Session III: “Balancing Pricing Regulations and Patient Access” Moderated by: Dr. Mouza Alsaadi, Health Economist - Dubai Health Authority, UAE Prof. Suliman Alghnam, Chair of ISPOR Arab Network Executive Director of Surveillance, Saudi Public Health Authority- KSA
By: Prof. Zaheer-Ud-Din Babar, Professor of Clinical Pharmacy and Practice, The University of Huddersfield, UK and Qatar University, Member of WHO Technical Advisory Group (TAG) On Pricing Policies for Medicines Qatar and UK
Balancing Pricing Regulations and Patient Access: Sharing Experience
Session III: “Balancing Pricing Regulations and Patient Access” Moderated by: Dr. Mouza Alsaadi, Health Economist - Dubai Health Authority, UAE Prof. Suliman Alghnam, Chair of ISPOR Arab Network Executive Director of Surveillance, Saudi Public Health Authority- KSA
By: Dr. Asmaa Saad, Head of Pricing Policy Administration and Pharmacoeconomics Unit in Egyptian Drug Authority, Egypt
Key Pillars for a Strategic Framework for Managed Entry Agreements Implementation
Session III: “Balancing Pricing Regulations and Patient Access” Moderated by: Dr. Mouza Alsaadi, Health Economist - Dubai Health Authority, UAE Prof. Suliman Alghnam, Chair of ISPOR Arab Network Executive Director of Surveillance, Saudi Public Health Authority- KSA
By: Prof. Hussain Al Omar, Professor of Pharmacoeconomics and Pharmaceutical Policy and Consultant, Department of Clinical Pharmacy, College of
Pharmacy, King Saud University- Senior Advisor and Expert in Health Technology Assessment, Health Economics, and Health Policy, KSA
Industry Symposium: Unveiling the hidden burden of Chronic spontaneous Urticaria
By: Dr. Mohamed Madbouly, Consultant Dermatologist and head of department at NMC Royal Abu Dhabi, UAE
Opening Speech
ISPOR UAE Conference 2025 official Opening
Prof. Nadia Al Mazrouei, ISPOR UAE Chapter President and Conference Chair, Expert Advisory Board Panel at WHO, Associate Professor at Sharjah University, EMR Pharma Forum President at FIP International, President of Pharmacists Association, UAE
ISPOR UAE Conference 2025 official Opening
Dr Mohamed Tannira, ISPOR UAE Chapter President Elect
ISPOR UAE Conference 2025 official Opening
Prof. Mohamed Farghaly ISPOR UAE Chapter Board Director and Head of Scientific committee, Professor Dubai Medical College, Consultant Family Medicine
ISPOR UAE Conference 2025 official Opening
Prof. Samar Mansour, Professor at GUC and GIU- ISPOR UAE Chapter Board of Director and Co- Chair of Scientific committee Healthcare Transformation Consultant, Egypt
ISPOR UAE Conference 2025 official Opening
Dr. Rob Abbott, CEO and Executive Director of ISPOR International
ISPOR UAE Conference 2025 official Opening
Dr. Robert Selby, Senior Director, Global Engagement ISPOR International
Session IV: “MENA Health Policy: Innovation Through Collaboration”
Opening Presentation for the Panel: HTA implementation, key success ingredients and challenges in MENA countries
Session IV: “MENA Health Policy: Innovation Through Collaboration” Moderated by Prof. Samar Mansour, Professor at GUC and Dean at German International University- ISPOR UAE Chapter Board Director and Co-Chair of Scientific committee- Healthcare Transformation Consultant
By: Dr. Mouna Jameleddine, Director of HTA department at the Tunisian Authority for Assessment and Accreditation in Healthcare (INEAS), Vice chair of INAHTA (the International Network of Agencies for HTA), WHO Expert,Tunisia
Collaborative Health Policy in MENA: Regional Partnerships for Innovation and System Efficiency “HEOR Shared Experience for Best Practice”
Session IV: “MENA Health Policy: Innovation Through Collaboration” Moderated by Prof. Samar Mansour, Professor at GUC and Dean at German International University- ISPOR UAE Chapter Board Director and Co-Chair of Scientific committee- Healthcare Transformation Consultant
Chairperson:
Prof. Samar Mansour, Professor at GUC and Dean at German International University- ISPOR UAE Chapter Board Director and Co-Chair of Scientific committee Healthcare Transformation Consultant, Egypt
Panelists:
Dr. Ahmed Seyam, Deputy CEO for Technical Affairs - Universal Health Insurance Authority- Egypt
Prof. Amal Sedrak, Director of the Central Administration of HTA – UPA- Egypt
Dr. Anas Hamad, Director of Pharmacy, NCCCR; Head of Medication Safety/Quality and Head of Pharmacy Research, HMC; Clinical Associate Professor, QU; Lead of HTA Project, MOPH, Qatar
Prof. Hussain Al Omar, Professor of Pharmacoeconomics and Pharmaceutical Policy and Consultant, Department of Clinical Pharmacy, College of Pharmacy, King Saud University- Senior Advisor and Expert in Health Technology Assessment, Health Economics, and Health Policy, KSA
Dr. Khadeija Al-Marshoudi, ISPOR UAE Chapter Board Director, Head of Planning and Development Section at Emirates Health Service, UAE
Dr. Meriem Hedibel, Research Assistant Professor at Algiers University, Algeria
Dr. Mouna Jameleddine, Director of HTA department at the Tunisian Authority for Assessment and Accreditation in Healthcare (INEAS), Vice chair of INAHTA (the International Network of Agencies for HTA), WHO Expert, Tunisia
Session V: “AI Meets Digital Health: Reshaping HEOR for a Smarter Future”
“Pharmacy in a changing environment Artificial Intelligence and Digital Health”
Session V: “AI Meets Digital Health: Reshaping HEOR for a Smarter Future” Moderated by: Dr. Bandar Al Harbi- Director of Pharmaceutical Services at Prince Sultan Military Medical City-KSA By: Dr. Lars- Ake- Söderlund Vice President International Pharmaceutical Federation (FIP), Sweden
“AI-Driven Frameworks and Real-World Data: Transforming HEOR, HTA, and Policy Decisions”
Session V: “AI Meets Digital Health: Reshaping HEOR for a Smarter Future” Moderated by: Dr. Bandar Al Harbi- Director of Pharmaceutical Services at Prince Sultan Military Medical City-KSA By: Dr. Abeer Al-Rabayah, Head of Center for Drug Policy and Technology Assessment, Pharmacy Department. King Hussein Cancer Center (KHCC), Jordan
Frontiers in HEOR: Transforming Outcomes and HTA – AI-Driven Assessment Frameworks and Regional Case Studies for Policy and Industry Leaders
Chair Person:
Dr. Abeer Al-Rabayah, Head of Center for Drug Policy and Technology Assessment, Pharmacy Department. King Hussein Cancer Center (KHCC), Jordan
Panelists :
Dr.AboBakr Abasaeed, ISPOR UAE Chapter Board Director-Regulatory Affairs Manager at ADCAN Pharma UAE
Dr. Bandar Al Harbi, Director of Pharmaceutical Services at Prince Sultan Military Medical City- KSA
Dr. Heba Mohamed, Pharmacy Program Chair, Higher Colleges of Technology, UAE
Dr. Nicole Gebran, Senior Specialist, Clinical Pharmacy Lead, Dubai Health- UAE
Session VI: “Unlocking Insights with Real-World Evidence (RWE)”
